Preclinical and clinical evidence for suppression of alcohol intake by apremilast

Preclinical and clinical evidence for suppression of alcohol intake by apremilast

Treatment options for alcohol use disorders (AUDs) have minimally advanced since 2004, while the annual deaths and economic toll have increased alarmingly. Phosphodiesterase type 4 (PDE4) is associated with alcohol and nicotine dependence. PDE4 inhibitors were identified as a potential AUD treatment...

Full description

Bibliographic Details
Main Authors: Kolter B. Grigsby, Regina A. Mangieri, Amanda J. Roberts, Marcelo F. Lopez, Evan J. Firsick, Kayla G. Townsley, Alan Beneze, Jessica Bess, Toby K. Eisenstein, Joseph J. Meissler, John M. Light, Jenny Miller, Susan Quello, Farhad Shadan, Michael Skinner, Heather C. Aziz, Pamela Metten, Richard A. Morrisett, John C. Crabbe, Marisa Roberto, Howard C. Becker, Barbara J. Mason, Angela R. Ozburn
Format: Article
Language:English
Published: American Society for Clinical Investigation 2023-03-01
Series:The Journal of Clinical Investigation
Subjects:
Clinical trials
Neuroscience
Online Access:https://doi.org/10.1172/JCI159103

Internet

https://doi.org/10.1172/JCI159103

Similar Items